The Pharmacy Examining Board regulates the following professions. Please click on the appropriate link below for further information.
Executive Director: Dan Williams
Related Board Information
| || |
Please note recently enacted legislation:
- Act 18 relating to chart orders and repealing the requirement to display license and Administrative rules related to some of the required equipment in a pharmacy
- Act 19 relating to prescription order extensions for when a refill authorization cannot be obtained.
- Act 25 relating to prohibiting Schedule V narcotic drugs containing nonnarcotic active medicinal ingredients from being dispensed without a prescription.
On October 1, 2016 the following Pharmacy Chapters were updated:
Phar 1, 8 Relating to Definitions and Controlled Substances
Phar 1, 2 and 4 Relating to Application and Examination
Phar 5 Relating to Renewal and Reinstatement
Phar 8 Relating to Identification Card Required for Certain Controlled Substances
|2015 Act 313 went into effect on April 1, 2016. This Act no longer authorizes the Pharmacy Board to grant variances unless a disaster or emergency exists, but to instead institute pilot projects. The Board is currently engaged in the transitioning of current non-emergency variances into pilot projects. Please see the link for more detailed information as to the Statutory requirements. http://docs.legis.wisconsin.gov/document/statutes/450.02(3r). |
|CSB 4.04 (2) (p) goes into effect on April 9, 2017. This requires that the name recorded under s. 450.11 (1b) (bm), Stats. be submitted to the Prescription Drug Monitoring Program.|
|2015 Act 291 relating to prescription fills and refills went into effect on April 1, 2016. |
Please review the following update:
NTSB Information on Risk of Pilot Impairment
|As of September 1, 2014, Phar 8.05(4), 8.07(2) and 8.09 were amended to allow electronic prescriptions for|
schedule II controlled substances.
On August 28, 2014 the DEA published its final rule in the Federal Register placing Suvorexant into Schedule IV of the Federal Controlled Substances Act. The scheduling action was effective September 29, 2014. The Wisconsin Controlled Substances Board pursuant to s. 961.11(4), Stats took affirmative action to treat Suvorexant as a Schedule IV effective November 1, 2014.
On August 22, 2014 the DEA published its final rule in the Federal Register rescheduling hydrocodone combination products from Schedule III to Schedule II of the Federal Controlled Substances Act. The scheduling action was effective October 6, 2014. The Wisconsin Controlled Substances Board pursuant to s. 961.11(4), Stats took affirmative action to similarly reschedule hydrocodone combination products from Schedule III to Schedule II effective November 1, 2014.
On July 2, 2014, the DEA published its final rule in the Federal Register placing tramadol into schedule IV of the federal Controlled Substances Act effective August 18, 2014. The Wisconsin Controlled Substances Board pursuant to s. 961.11(4), Stats took affirmative action to similarly treat tramadol as a schedule IV controlled substance effective September 1, 2014.
As of November 1, 2013, Phar 7.01(1)(e), Wis. Admin. Code, relating to delivery, became effective.